首页> 外文期刊>Journal of analytical research in clinical medicine. >COVID-19; critical care challenges in resource-limited countries
【24h】

COVID-19; critical care challenges in resource-limited countries

机译:新冠肺炎; 资源有限国家的重大关心挑战

获取原文
       

摘要

On January 30, 2020, World Health Organization (WHO) declared the outbreak of novel coronavirus disease 2019 (COVID-19) as a Public Health Emergency of International Concern (PHEIC). Now, the COVID-19 has been found in almost all countries across the world (Figure 1). Evolving situation in resourcelimited countries (RLCs) is very concerning. Most of the guidelines are developed in high income countries (HICs) which are totally different from RLCs regarding economic situation, healthcare standards, genetic factors and virulence. About 69% of population ≥60 years old, as a suspectable group for sever illness and death due to COVID-19, are in these countries.1 This is very alarming and troublesome in RLCs which have already obstacles in providing basic primary healthcare such as maternal and childhood health or vaccination programs. Since most of the RLCs do not already have a preparedness plan for outbreaks, the challenges to suppress COVID-19 spread may become insuperable. Denial of the pandemic in Latin American countries leads to lack of coordination and delayed effective steps such as lockdown and also misuse of medications.2 In Middle East countries, armed conflicts in the region targets health care facilities of borders and destroys them.
机译:2020年1月30日,世界卫生组织(世卫组织)宣布爆发2019年(Covid-19)作为国际问题(PHEIC)的公共卫生应急。现在,Covid-19几乎在全球各国发现(图1)。资源经历的国家(RLC)的不断发展局势非常有关。大多数准则都是在高收入国家(HICS)中制定的,与RLC完全不同于关于经济形势,医疗保健标准,遗传因素和毒力。大约69%的人口≥60岁​​,作为Covid-19由于Covid-19由于Covid-19而导致的可疑群体.1这是在RLC中非常令人惊叹和麻烦,在提供基本的主要医疗保健方面的障碍母婴健康或疫苗接种计划。由于大多数RLC尚未对爆发进行准备计划,因此抑制CoVID-19蔓延的挑战可能会被耐受。拒绝拉丁美洲国家的大流行导致缺乏协调和延迟有效步骤,如中东国家的药物,该地区的武装冲突为边界的医疗保健设施造成卫生保健设施并摧毁它们。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号